Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the approvals for drug production and registration for Moxifloxacin Hydrochloride Eye Drops and Levofloxacin & Sodium Chloride Injection from the National Medical Products Administration of China, both being under type 4 chemical drug and regarded as passing the consistency evaluation.

Moxifloxacin Hydrochloride Eye Drops is mainly used for treatment of bacterial conjunctivitis caused by susceptible micro-organisms, and is the Group's first approved ophthalmic preparation dosage form. Levofloxacin belongs to quinolone antibiotics and is mainly used for treatment of respiratory system infections, urinary system infections, reproductive system infections, skin soft tissue infections, intestinal infections and other infections caused by susceptible bacteria.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 18 March 2022

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.